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Background: Refractory post cardiopulmonary bypass (CPB) bleeding continues to cause 
concern for cardiac surgeons and intensivists. Massive postoperative hemorrhage following CPB 
is multifactorial and not fully understood, and it is also associated with increased mortality and 
morbidity. Activated recombinant factor VII (rFVIIa) has emerged as possible salvage medica-
tion in refractory post cardiac surgical bleeding. This observational study sought to identify the 
pattern of use of rFVIIa in cardiac surgery, its effectiveness, and risk.
Methods: This study involved a retrospective case review of medical records of ten patients 
undergoing a variety of cardiac surgery procedures and who developed life-threatening bleed-
ing during surgery or after surgery despite conventional medical therapy, including transfusion 
of blood and blood products, and received rFVIIa at a regional center between August 2007 
and April 2009.
Results: All ten patients received two consecutive doses of rFVIIa (average dose 65 µg/kg) 
at a 2-hour interval. Eight patients were re-explored due to massive postoperative bleeding 
or cardiac tamponade before receiving rFVIIa. Surgical sources of bleeding were not identi-
fied in any cases. A second re-exploration was carried out in two cases. Two patients (20%) 
died in ITU from problems not related to bleeding and thromboembolism. Blood loss was 
significantly reduced after administration of rFVIIa. Blood loss 6 hours prior to treatment was 
1758.5 ± 163.9 mL and blood loss in the 6-hour period post treatment was 405.6 ± 50.5 mL 
(P , 0.05). Blood and blood products used in the 6-hour period before and after administration 
of rFVIIa were 19.6 ± 1.5U and 4.4 ± 0.6U, respectively (P , 0.05). No adverse reactions or 
thrombotic complications related to rFVIIa were noted.
Conclusion: In our limited study, use of rFVIIa in refractory post surgical bleeding was sig-
nificantly reduced blood loss and use of blood and blood products. We concluded that rFVIIa 
can be used satisfactorily and safely as a rescue therapy in the management of post cardiac 
surgical bleeding.
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Introduction
After cardiac surgery, excessive bleeding occurs in 15% of patients. Among them 20% 
require blood products, re-exploration, or both. In spite of standard therapy, blood 
loss continues in 2% of cases. Massive blood loss, multiple blood transfusion, and 
re-exploration required in such cases are associated with multiple organ failure and 
prolonged hospital stay.1
Refractory postoperative bleeding is a life-threatening complication following 
cardiac surgery and presents a challenge for surgeons, anesthetists and perfusionists. 
Refractory bleeding is resistant to ordinary methods of treatment, ie, transfusion of Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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blood and blood products to correct coagulation profiles. 
The patients developed continued brisk blood loss in chest 
drain despite correction of coagulopathy, hypothermia, 
and surgical re-exploration. Multiple factors contribute to 
  bleeding following cardiac surgery. Surgical site bleed-
ing is the primary cause and can be limited by meticulous 
hemostasis. But the most common reason for uncontrolled 
bleeding is derangement of the coagulation pathway. During 
cardiopulmonary bypass (CPB), the complement cascade, the 
kinin system, and the coagulation system are all activated 
and could result in refractory bleeding. In addition, patients 
who undergo emergency coronary surgery are more likely 
to have been treated with thrombolytic agents, high dose 
heparin, and high doses of antiplatelet drugs, all of which 
could accentuate a coagulopathy after surgery.
With CPB, microvascular bleeding develops secondary 
to acquired hemostatic system abnormalities that include: 
(1) hemodilution secondary to volume resuscitation or loss of 
platelets and coagulation factors; (2) effects of hypothermia 
on both plasma coagulation factors and platelet function; 
(3) consumption coagulopathy due to tissue injury, contact 
activation, and transfusion of shred pericardial blood; and 
(4) residual heparin or heparin rebound.2
Treatment of postoperative bleeding involves exclu-
sion of a surgical source of bleeding and the identification 
and treatment of specific coagulation abnormalities, in 
combination with the use of thrombogenic agents such as 
tranexamic acid and protamine. Activated recombinant factor 
VII (rFVIIa) (NovoSeven®, Novo Nordisk, Inc, Bagsværd, 
Denmark) is used as rescue therapy after all conventional 
therapy has failed.
The aim of this study was to review our use of rFVIIa for 
refractory bleeding after cardiac surgery.
Methods
This retrospective study was carried out from a review of 
the medical records of all patients who received rFVIIa for 
refractory postoperative bleeding following cardiac surgery 
at a regional center between April 2007 and April 2009. 
During this period, ten patients received rFVIIa, six males 
and four females, with a median age of 72.5 years (range 
59–81 years). Seven patients were on anticoagulant therapy 
on the day of surgery: three on aspirin, one on unfractionated 
heparin, two on clopidogrel, and one had been treated with 
intravenous unfractionated heparin, aspirin, and clopidogrel 
on the day of surgery. None of the patients had a history of 
bleeding or clotting disorders. Patients’ demographics are 
outlined in Table 1.
Thrombogenic treatment
In our center, conventional medical therapy to achieve hemo-
stasis starts with tranexamic acid at the beginning and end 
of the operation. For reversal of heparin after weaning from 
CPB, protamine is given at a dose of 1 g per 100 units of 
heparin. Further doses of protamine are administered either to 
achieve the pre-operative activated clotting time (ACT) or an 
ACT , 130 seconds. None of the patients received aprotinin 
or desmopressin. Fresh frozen plasma, platelets, and red cell 
concentrates were used as appropriate, based on laboratory 
results of the coagulation screen. For refractory bleeding, 
rFVIIa is administered at a mean intravenous bolus dose of 
65 µg/kg (range 55–80 µg/kg). Acidosis and hypothermia 
were corrected before administration of rFVIIa.
Dose of rFViia
All ten patients received two consecutive doses of rFVIIa. 
NovoSeven is available in the hospital in 1.2, 2.4, and 5 mg 
vials. According to body weight, 65 µg/kg rFVIIa was admin-
istered after identification of refractory bleeding. This same 
dose was repeated after 2 hours.
statistical analysis
Data are expressed as mean ± standard error of the mean, or 
median (range). Continuous variables were compared with 
paired t-test after Kolmogorov–Smirnov test to confirm the 
presence of a normal distribution. Analyses were performed 
using SPSS Statistics software (v 19.0; IBM Corporation, 
Somers, NY). Differences were considered to be statistically 
significant if P , 0.05.
Results
surgical procedure
Ten patients underwent cardiac surgery with CPB; four were 
elective, and six were emergency procedures. The median CPB 
time was 125 minutes (range 275–60   minutes), and median 
cross-clamp time was 66 minutes (range 191–20   minutes). 
The mean European System for cardiac operative risk evalu-
ation score (EuroSCORE) was 6.9 ± 0.9, and mean logistic 
EuroSCORE was 8.3 ± 1.7. Two patients underwent aortic 
root surgery, and the rest of the patients underwent coronary 
artery surgery.
Bleeding
Bleeding was controlled eventually in all patients. Eight 
patients were re-explored due to massive postoperative 
bleeding or cardiac tamponade. Surgical sources of bleeding 
were not identified in any cases. A second re-exploration was Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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carried out in two cases. Blood loss was significantly reduced 
after administration of rFVIIa. Blood loss 6 hours prior to 
treatment was 1758.5 ± 163.9 mL, and blood loss in the 6-hour 
period post treatment was 405.6 ± 50.5 mL (P , 0.05).
Blood products
All patients received blood and blood products after bleeding. 
The amount of blood and blood product reduced significantly 
after administration of rFVIIa. Blood and blood products used 
in the 6-hour period before and after administration of rFVIIa 
were 19.6 ± 1.5 U and 4.4 ± 0.6 U respectively (P , 0.05). 
No adverse reactions or thrombotic complications related to 
rFVIIa were noted.
Discussion
In this limited series, we noted a reduction in the rate of 
blood loss in all cases. There were no nonresponders. 
Although the use of rFVIIa was not randomized with a 
control arm, this consistency in response following admin-
istration of the drug suggests a cause-and-effect rather than 
a simple association. As suggested by previous reports, 
we attempted in all cases to correct coagulopathy with the 
use of clotting factors and avoid the use of this drug in the 
presence of acidosis.
Guidelines on blood conservation clinical practice state 
that “factor VIIa may be considered for the management of 
intractable bleeding that is unresponsive to routine   hemostatic 
therapy”.3 Although there have been case reports and observa-
tional studies, there are no clear-cut guidelines on appropriate 
dose or the timing of use of this drug.
The patients received a mean dose of 65 µg/kg within 
2 hours of refractory bleeding. The timing of its use is crucial 
due to the perquisite requirement of the presence of adequate 
circulating clotting factors for effectiveness of rFVIIa. This is 
consistent with observations of other groups that have noted 
an increased effectiveness with the use of rFVIIa earlier and 
in presence of adequate coagulation factors.4
rFVIIa stimulates the coagulation cascade by activation of 
thrombin at the site of tissue injury by tissue factor-dependent 
and -independent mechanisms (when 10-fold higher doses 
of factor VIIa are available in the vicinity).5 Tissue factor is 
exposed on the subendothelial surface and on the surface of 
neutrophils, monocytes, and platelets during an inflammatory 
response. A tissue factor-dependent mechanism results in 
factor X activation, and activated factor X in   combination with 
factor V leads to the generation of thrombin. It is also reported 
that rFVIIa can directly activate factor X on   phospholipid 
vesicles, activated monocytes, and on the platelet surface with-
out the presence of tissue factor.6 This tissue factor-independent 
mechanism of thrombin formation is also valuable. All of the 
enhanced thrombin generation results in recruitment, activa-
tion, and aggregation of platelets, that results in formation of 
stabilized clots, which are resistant to fibrinolysis. However, 
severe hypothermia (33°C) and acidosis (pH , 7.2) reduce 
the effect of factor VII, so these must be corrected prior to 
administration of rFVIIa.
Significant concerns have arisen over the safety, efficacy, 
and cost of the use of rfVIIa in cardiac surgical patients.7–9 
The interaction of rFVIIa with antifibrinolytic drugs could 
potentially increase the risk of life-threatening thrombotic 
events. Raivio et al has demonstrated 25% mortality and 
25% thrombotic events after administration of rfVIIa.10 
Other groups have reported 5%–32% mortality rate4,7,11 and 
4%–5.3% rate of thromboembolic events.9,11,12 In our series 
we did not encounter any thromboembolic events. There 
were no episodes of thrombotic graft occlusion despite 
the presence of significant coronary artery disease (80%). 
The variations in the adverse event rates suggest that these 
Table 1 Patient demographics
Age Sex EuroSCORE Logistic  
EuroSCORE
HTN DM Coronary  
artery disease
PVS Renal  
disease
Name  
of operation
Emergency/ 
elective
63 M 1 1.15 Yes No 3VD Yes No CABG elective
59 F 5 4.17 Yes No 2VD No No CABG emergency
75 F 9 11.19 Yes Nes No Yes Yes AVr emergency
75 M 8 8.33 Yes No 3VD No No CABG emergency
81 M 9 11.28 Yes No 2VD No Yes Arr+AVr+CABG elective
74 F 10 18.45 Yes No No No Yes AVr emergency
71 M 7 6.52 Yes No 2VD No No AVr+CABG elective
59 M 4 3.03 Yes No 3VD No No CABG emergency
64 F 6 4.87 Yes Yes 2VD No No Arr+AVr+CABG elective
76 M 10 14.32 Yes Yes 3VD Yes No CABG emergency
Abbreviations: HTN, hypertension; DM, diabetes mellitus; PVs, peripheral vascular disease; CABG, coronary artery bypass graft; Arr, aortic root replacement; AVr, aortic 
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are likely to be multifactorial with pre-existent morbidity, 
complexity of surgery, presence of underlying and perhaps 
undiagnosed coagulopathy, and dose of prothrombotic drugs 
playing a role. We noted a mortality rate of 20% in this series. 
Once again, the variations in the mortality rates reported by 
other groups make it difficult to ascertain whether mortality 
was a direct result of the use of this drug or the presence of 
comorbid conditions as well as the length and complexity of 
the operative procedure. In our series, none of the patients 
died as a direct result of the hemorrhage.
We used an average dose of 65 µg/kg on our patients 
in this series, in keeping with recommendations by other 
groups.4,13 With the off-label use of this drug in patients fol-
lowing cardiac surgery, there are no recommendations from 
the manufacturer on appropriate dosing schedule. However, in 
this series, we noted a response in all patients with the use of 
65 µg/kg. Other groups have noted an increased incidence of 
adverse effects with the use of higher doses of the drug.4,14
In theory, a randomized control trial (RCT) is necessary 
to remove doubts over the effectiveness of this drug, serious 
adverse events directly related to its use and optimum   timing 
of use. In practice, however, an RCT is difficult to carry 
out due to the infrequent occurrence of refractory bleeding 
  following cardiac surgery and the critical nature of this clini-
cal situation. The identification of patients in whom the use of 
factor VIIa are likely to be of value can be more realistically 
identified by case-series and observational studies.
Limitations
The limitations of our studies are single institution basis, 
lack of control population, modest sample size, and relatively 
short follow-up period. The desirable outcomes, minimal 
complications, and patient tolerance suggest that rFVIIa can 
be used effectively as rescue therapy in refractory bleeding 
after cardiac surgery.
Conclusion
In our series, rFVIIa was associated with a reduction 
in blood loss and reduced need for transfusion of blood 
  products. No thromboembolic events were noted following 
its   administration. We conclude that this case series gives 
better understating of rFVIIa administration in refractory 
bleeding in cardiac surgery. Multicenter, RCTs are prereq-
uisite for firm conclusions regarding appropriate dosing 
regime and safety profile of rFVIIa in cardiac surgery 
patients.
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